[DOI] [PMC free article] [PubMed] [Google Scholar] 72.Control G, et al
This is the first key shift in perspective: GLP-1 medications are system-level metabolic therapies, not simply appetite suppressants
The next generation of oral GLP-1s, such as Orforglipron and high-dose oral semaglutide, are showing weight loss results in trials that are much closer to those of their injectable counterparts
In an antimicrobial context, this could tentatively be interpreted as ApoE playing a role in coordinating metal ions to alter A aggregation dynamics toward increased cytotoxic aggregate formation to increase As antimicrobial efficacy (either alone or in synergy with other AMPs and copper), for which ApoE4 might exert the strongest synergistic AMP effect due to its copper-A interaction and its ability stabilize cytotoxic A oligomers/fibrils (Garai et al., 2014)
Treatment with exenatide has been shown to decrease food intake and attenuate food-related neural responses in key regions such as the insula, amygdala, putamen, and orbitofrontal cortex (van Bloemendaal et al., 2014)
)
